Search Medical Condition
Please enter condition
Please choose location

Wigan, United Kingdom Clinical Trials

A listing of Wigan, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (25) clinical trials

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.0 miles

Learn More »

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

Phase 1 (n=9-12) As fulvestrant and AZD5363 have not previously been administered to this population, we have incorporated an initial phase I dose escalation: - 3 patients will receive fulvestrant 500mg on day 1 and 400mg AZD5363 oral capsules or tablets bd 4 days on and 3 days off. They ...

Phase

0.0 miles

Learn More »

14022 ATTUNE Cementless RP Clinical Performance Evaluation

The secondary objectives of this study are: - Evaluate change from preoperative baseline in post-operative outcomes using additional patient reported measures at 2 years: PKIP (overall and sub-scores), KOOS (overall and sub-scores), AKS and EQ-5D-3L. - Evaluate change from preoperative baseline in pain and satisfaction over time as measured using ...

Phase N/A

0.0 miles

Learn More »

A Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

The total study duration per patient is expected to be up to 52 weeks that will consist of a 4-week run-in period, 24-week treatment period, and a 24-week posttreatment period.

Phase

0.87 miles

Learn More »

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage) Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

This multicenter study uses a randomized, double-blind, placebo-controlled, parallel-group design. A screening period (SCR) running up to 10 weeks before randomization will be used to assess subject eligibility followed by 104 weeks of treatment. At BSL approximately 990 subjects whose eligibility is confirmed will be randomized to one of four ...

Phase

4.52 miles

Learn More »

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis

This is a prospective, observational, cohort study to collect data on adult participants who have a confirmed diagnosis of psoriatic arthritis (PsA) and are starting either STELARA or a new TNFi as a new therapy in a first, second, or third line of biologic disease-modifying antirheumatic drug (bDMARD) therapy. Approximately ...

Phase N/A

4.52 miles

Learn More »